SC allowed classification of Odomos under HSN 38089191 to stand, holding that market identity and consumer understanding ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...

Whooping cough is spreading at this California school, infecting several people with the ancient disease, as health officials ...

Chronic viral infections, including HPV, HIV, viral hepatitis, and herpesviruses, affect over a billion people worldwide and are responsible for millions of ...

The convergence of rapid environmental change and emerging infectious diseases presents an urgent challenge for global public health. Harnessing advances in ...

GLP-1 agonists have become the dominant spend catalyst, with class spending ~$132B and growth contribution approaching ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Bambusa's lead product candidate, BBT001 is a next-generation long-acting bispecific antibody targeting two clinically and ...

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late ...